Treatment Performance Measures Affect Clinical Outcomes in Patients With Acute Systolic Heart Failure : Report From the Korean Heart Failure Registry

この論文にアクセスする

この論文をさがす

著者

    • YOUN Young Jin
    • Division of Cardiology, Yonsei University Wonju Christian Hospital
    • YOO Byung-Su
    • Division of Cardiology, Yonsei University Wonju Christian Hospital
    • LEE Jun-Won
    • Division of Cardiology, Yonsei University Wonju Christian Hospital
    • KIM Jang-Young
    • Division of Cardiology, Yonsei University Wonju Christian Hospital
    • JEON Eun-Seok
    • Division of Cardiology, Sungkyunkwan University Samsung Medical Center
    • KIM Jae-Joong
    • Division of Cardiology, Ulsan University Asan Medical Center
    • KANG Seok-Min
    • Division of Cardiology, Yonsei University Severance Hospital
    • CHOI Dong-Ju
    • Division of Cardiology, Seoul National University Bundang Hospital

抄録

<b><i>Background:</i></b> There is a paucity of data on the effects of adherence to treatment on outcomes for patients with acute heart failure (HF) in Korea. We used HF performance measures to evaluate overall adherence and whether this affects clinical outcomes. <b><i>Methods and Results:</i></b> Among 3,466 patients in the Korean Heart Failure Registry, 1,527 patients with left ventricular systolic dysfunction (LVSD) who survived hospitalization were evaluated. Modified validated performance measures were defined as follows: use at discharge of angiotensin-converting enzyme inhibitor (ACEI), angiotensin-receptor II blocker (ARB), β-blocker or aldosterone receptor antagonist. Adherence to performance measures were as follows: ACEI or ARB at discharge, 68.0%; β-blocker at discharge, 40.9%; aldosterone receptor antagonist at discharge, 37.5%. On multivariate analysis, adherence to the measure of ACEI or ARB use at discharge was significantly associated with mortality (odds ratio (OR), 0.344; 95% confidence interval (CI), 0.123-0.964), readmission (OR, 0.180; 95%CI, 0.062-0.522) and mortality/readmission (OR, 0.297; 95%CI, 0.125-0.707) at 60 days and that for β-blocker with mortality (OR, 0.337; 95%CI, 0.147-0.774) at 1 year. <b><i>Conclusions:</i></b> For patients with LVSD in Korea, adherence to treatment performance measures, including prescription of an ACEI/ARB and β-blocker use at discharge, is associated with improved clinical outcomes. (<i>Circ J</i> 2012; <b>76:</b> 1151-1158)<br>

収録刊行物

  • Circulation journal : official journal of the Japanese Circulation Society

    Circulation journal : official journal of the Japanese Circulation Society 76(5), 1151-1158, 2012-04-25

    一般社団法人 日本循環器学会

参考文献:  41件中 1-41件 を表示

被引用文献:  1件中 1-1件 を表示

各種コード

  • NII論文ID(NAID)
    10030132492
  • NII書誌ID(NCID)
    AA11591968
  • 本文言語コード
    ENG
  • 資料種別
    ART
  • ISSN
    13469843
  • データ提供元
    CJP書誌  CJP引用  J-STAGE 
ページトップへ